Iowa House Bill HSB151

Iowa 2025-2026 Regular Session

• Introduced: 2/11/25
• Refer: 2/11/25

Caption

A bill for an act relating to nonopioid drugs on the medical assistance preferred drug list, and health carriers' development of a pain management access plan.

Summary

HSB151 would change Iowa Medicaid and private health insurance rules to promote access to nonopioid pain treatments. For Medicaid, the bill requires that FDA-approved nonopioid drugs for pain not be disadvantaged on the preferred drug list compared with opioid or narcotic pain drugs. It bars placing a nonopioid pain drug in a less favorable tier if an opioid pain drug is preferred, and it limits prior authorization, step therapy, and other utilization controls so nonopioids cannot face more restrictive requirements than the least restrictive controls applied to opioids. These protections would apply immediately upon FDA approval for pain treatment, even before review by the pharmaceutical and therapeutics committee, and would also apply to drugs covered through Medicaid managed care contracts. The bill also creates a new requirement for health carriers to develop and implement a pain management access plan. That plan must cover at least two FDA-approved noncontrolled prescription alternatives for pain and at least three nonpharmacologic pain treatment options. It must also avoid imposing more restrictive utilization controls on clinically appropriate nonopioid pain drugs than on opioid or narcotic pain drugs. Health carriers would have to file the plan with the insurance division for approval, provide annual educational materials to providers and covered persons, and make the plan publicly available online. The insurance commissioner would be authorized to adopt rules to administer the new requirements.

Impact

HSB151 would amend Iowa Code section 249A.20A governing Medicaid preferred drug lists and add a new section to chapter 505 requiring pain management access plans for health carriers. The practical effect is to limit the ability of Medicaid and private insurers to favor opioids over nonopioid pain treatments through formulary placement or utilization management. It would also expand oversight by the insurance division and create new compliance, filing, disclosure, and rulemaking obligations for insurers and managed care arrangements.

Sentiment

Based on the bill text and the absence of recorded committee testimony or votes, the bill appears to reflect a policy preference for reducing opioid reliance and improving access to alternative pain treatments. The structure of the bill suggests a consumer- and public-health-oriented approach, with an emphasis on ensuring coverage for nonopioid and nonpharmacologic options. No contrary viewpoints are documented in the provided materials, so there is no recorded formal opposition or support to gauge beyond the bill’s apparent intent.

Contention

The main points of potential contention are the bill’s restrictions on formulary design and utilization management. Medicaid administrators, managed care organizations, and health carriers may view the bill as limiting their flexibility to use prior authorization, step therapy, and preferred/nonpreferred tiering to manage costs and clinical review. Another possible issue is the requirement that nonopioid drugs receive favorable treatment immediately upon FDA approval, before review by the pharmaceutical and therapeutics committee, which could be seen as reducing the state’s ability to evaluate coverage decisions. Supporters would likely emphasize the bill’s goal of preventing opioid preference and improving access to safer pain management alternatives.